Abstract
The ultimate goal of COVID-19 vaccination campaigns is to enable the return of societies and economies to a state of normality. While vaccines have been approved for children of age 12 and older, there is an ongoing debate as to whether children should be vaccinated and at what priority, with very different policies being adopted in different countries. In this work, we use mathematical modeling and optimization to study the effect of vaccinating children on the epidemic spread. We consider Pareto-optimal allocations according to competing measures of number of infections and mortality, and systematically study the trade-offs among them. When some weight is given to the number of infections, we find that it is optimal to allocate vaccines to adolescents in age group 10-19, even when they are assumed to be less susceptible than adults. Additionally, we find that in a broad range of scenarios, optimal allocations of vaccines do not include vaccination of age-group 0-9.
Author summary One of the acute questions public health experts and policymakers currently confront is whether children of age 12 and older, and eventually perhaps younger children, should be vaccinated against COVID-19, and at what priority. Different countries have adopted diverse policies on this issue, while others remain undecided. One of the key considerations in this debate is the impact of children’s vaccination on the epidemic spread. In this work, we use mathematical and computational methods to study this question in a systematic, quantitative way. We compute optimal vaccination allocations, under different criteria for optimality, both including and not including children. To explore tradeoffs among different goals, such as reducing number of infections and reducing mortality, we use the idea of Pareto optimization, which is novel in this field. Our results show that, under a wide range of conditions, optimal vaccine allocations include vaccination of age group 10-19, while the vaccination of age group 0-9 is of lower priority than the vaccination of other age group.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the ISRAEL SCIENCE FOUNDATION (grant No. 3730/20) within the KillCorona: Curbing Coronavirus Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work is based on the use of public aggregate data only and no medical intervention and is therefore exempt from institutional review board approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.